Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Diabetic Nephropathy: early-phase trial registry

2 of 10 indexed Diabetic Nephropathy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Diabetic Nephropathy: 10 US clinical trials tracked, 2 recruiting.

Diabetic Nephropathy is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Southeast Renal Research Institute, running 1 of these trials.

Enrollment posture brief

Registry condition diabetic-nephropathy

OPEN 2 | RECR 20% | LATE 2 | EARLY 5 | RANK #1724 | SPON 1

Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Diabetic Nephropathy (this)20%
Open-enrollment share among volume-matched conditions near Diabetic Nephropathy

Diabetic Nephropathy lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetic Nephropathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetic Nephropathy is recruiting below its size-band peers.

    2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Diabetic Nephropathy trials is spread across many organizations.

    Southeast Renal Research Institute accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetic Nephropathy enrolment sits around 226 participants.

    Median target enrolment is 226 among the 10 trials that report a genuine target (sentinel values excluded). 5 of those (50%) plan for fewer than 100 participants.

  4. Diabetic Nephropathy research is mostly interventional.

    8 interventional and 2 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24Phase 42

Open and recent trials

10 total, page 1 of 1

RECRUITING 100,000 participants

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00342927

RECRUITING 2,000 participants

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

The Rogosin Institute

NCT01802034

COMPLETED Phase 2 281 participants

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

Abbott

NCT00421733

COMPLETED Phase 2 227 participants

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Biogen

NCT00811889

COMPLETED Phase 2 226 participants

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Pfizer

NCT01712061

COMPLETED Phase 4 45 participants

Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes

University of Colorado, Denver

NCT02502071

COMPLETED Phase 2 34 participants

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

Mallinckrodt

NCT01601236

COMPLETED NA 30 participants

Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

Stanford University

NCT00240019

COMPLETED Phase 1 20 participants

Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy

Icahn School of Medicine at Mount Sinai

NCT00967629

COMPLETED Phase 4 15 participants

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

Southeast Renal Research Institute

NCT01028287

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 4 2

Named interventions

Most-linked intervention names on Diabetic Nephropathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
Bardoxolone Methyl (RTA 402) Drug
1 trials
PF-04634817 Drug
1 trials
Zemplar (paricalcitol) capsules Drug
1 trials
Zemplar (paricalcitol ) capsules Drug
1 trials
Sevelamer Carbonate Drug
1 trials
Calcium Carbonate Drug
1 trials
Addition of furosemide 20 mg oral bid to baseline regimen Drug
1 trials

US sites by state

Facility locations filed on Diabetic Nephropathy trials. A trial with sites in several states counts in each.

California 5 trials
New York 4 trials
Florida 4 trials
Tennessee 2 trials
Louisiana 2 trials
Illinois 2 trials
Georgia 2 trials
Colorado 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetic Nephropathy page

10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Nephropathy condition card totals 10 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.